Los Angeles Capital Management LLC Purchases 83,143 Shares of Xencor, Inc. $XNCR

Los Angeles Capital Management LLC increased its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 654.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 95,847 shares of the biopharmaceutical company’s stock after buying an additional 83,143 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Xencor were worth $753,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. State of Wyoming acquired a new stake in Xencor in the first quarter valued at approximately $34,000. CWM LLC raised its position in shares of Xencor by 195.5% during the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 2,231 shares during the period. AlphaQuest LLC bought a new position in shares of Xencor in the 1st quarter worth $56,000. US Bancorp DE grew its position in Xencor by 312.0% in the 1st quarter. US Bancorp DE now owns 10,432 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 7,900 shares during the period. Finally, Hsbc Holdings PLC acquired a new stake in Xencor in the 1st quarter valued at $119,000.

Xencor Price Performance

XNCR opened at $13.99 on Friday. Xencor, Inc. has a fifty-two week low of $6.92 and a fifty-two week high of $27.24. The firm has a market capitalization of $999.03 million, a P/E ratio of -5.83 and a beta of 0.99. The company’s 50-day moving average is $12.18 and its 200 day moving average is $9.79.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.64. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The business had revenue of $21.00 million during the quarter, compared to the consensus estimate of $29.73 million. During the same period in the prior year, the firm posted ($0.71) EPS. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, equities research analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on XNCR. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a report on Tuesday, October 14th. Wells Fargo & Company decreased their target price on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Bank of America lowered shares of Xencor from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $23.00 to $12.00 in a report on Wednesday, September 3rd. Cantor Fitzgerald lifted their price target on Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Finally, Wedbush reissued an “outperform” rating and set a $26.00 price objective on shares of Xencor in a report on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.63.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.